Picture Berlin Partner Life Sciences Report 2019/2020 Brandenburg 650x80px
Document › Details

CureVac AG. (11/8/16). "Press Release: CureVac Secures an Additional $29.5 Million From Two New Investors". Tübingen.

Organisations Organisation CureVac AG
  Group CureVac (Group)
  Organisation 2 Landeskreditbank Baden-Württemberg
  Group Baden-Württemberg (govt region)
Products Product RNActive® vaccination technology
  Product 2 venture capital
Index terms Index term CureVac–SEVERAL: investment, 201611 financing $29.5m led by new investors LBBW Asset (for BWVÄZT) + Landeskreditbank BW
  Index term 2 CureVac–SEVERAL: investment, 201511 private placement €100m led by Baillie Gifford
Persons Person Hoerr, Ingmar (CureVac 201806– Chairman of Supervisory Board before 2000–201806 CEO + Co-Founder)
  Person 2 Lauterbach, Verena (CureVac GmbH 201603 Senior Director Communications)

Baden-Württembergische Versorgungsanstalt für Ärzte, Zahnärzte und Tierärzte and Landeskreditbank Baden-Württemberg invest in CureVac‘s development of innovative drugs „made in Baden-Württemberg“

CureVac AG today announced that the company secured a total of $29.5 million in a financing led by new investors Baden-Württembergische Versorgungsanstalt für Ärzte, Zahnärzte und Tierärzte (via the LBBW Asset Management Investmentgesellschaft mbH, Stuttgart) and Landeskreditbank Baden-Württemberg. CureVac plans to utilize these funds to advance the development of its innovative messenger RNA (mRNA) product portfolio.

The new investors join earlier investors that participated in the company’s financing in November 2015, where CureVac raised a total of $110 million (€100 million). Additional information regarding the previous round can be found here.

Ingmar Hoerr, PhD, co-founder and CEO of CureVac stated, “We are happy to now have the support of two shareholders from the state of Baden-Württemberg, after having completed the last round of financing with five international investors. Their investment adds additional wind to our sails for our medical pioneering. We are currently testing our mRNA technology in various applications in order to translate our newest scientific findings into product development. We are firmly convinced that a medical revolution will take place due to mRNA technology and thereby entirely new drugs and applications can be made accessible to patients in the future.”

The latest round brings CureVac’s total capital raised since its inception in 2000 to approximately $360 million.

About CureVac AG

Founded in 2000 as a spin-off from the University of T?bingen in Germany, CureVac is a technology leader in the development of drugs that are based on the molecule Messenger RNA (mRNA). The company generated over more than 16 years a very advanced product pipeline and IP portfolio.

The basic principle of CureVac's proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. CureVac’s mRNA programs include novel mRNA-based cancer immunotherapies and prophylactic vaccines against infectious diseases (RNActive®), molecular therapies designed to trigger the body's own production of therapeutic proteins (RNArt®), a technology that enables the prolonged expression of functional antibodies and antibody-like proteins from mRNA (RNAntibody®) and a novel, RNA-based adjuvant therapy designed to enhance the immunogenicity of vaccines and proteins (RNAdjuvant®).
CureVac has entered into various collaborations with multinational corporations and organizations, including agreements with Boehringer Ingelheim, Sanofi Pasteur, the Bill & Melinda Gates Foundation and IAVI.

For more information, please visit


Media Contacts

Verena Lauterbach, Senior Manager Communications
CureVac AG, Tübingen, Germany
T: +49 (0) 7071 9883 1756

Andrew Mielach, Vice President
Tiberend Strategic Advisors, New York
T: +1 212 375 2694

Record changed: 2017-01-17


Picture Kentro Design Corporate and Web Design Berlin 650x65px

More documents for CureVac (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BioTech Showcase 2021 Digital Event BTS2021 651x81

» top